Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting
Luisa Prochazkova, Dominique P. Lippelt, Lorenza S. Colzato, et al.
Psychopharmacology (2018) Vol. 235, Iss. 12, pp. 3401-3413
Open Access | Times Cited: 153

Showing 26-50 of 153 citing articles:

The costs and benefits of psychedelics on cognition and mood
Ceyda Sayalı, Frederick S. Barrett
Neuron (2023) Vol. 111, Iss. 5, pp. 614-630
Open Access | Times Cited: 26
Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways
Jitendra Kumar Sinha, Anchal Trisal, Shampa Ghosh, et al.
Ageing Research Reviews (2024) Vol. 96, pp. 102211-102211
Closed Access | Times Cited: 13
Psychedelic therapy in depression and substance use disorders
Nur Damla Korkmaz, Uğur Çıkrıkçılı, Merve Akan, et al.
European Journal of Neuroscience (2024) Vol. 60, Iss. 2, pp. 4063-4077
Open Access | Times Cited: 10
Narrative identity, rationality, and microdosing classic psychedelics
Megan Webb, Heith Copes, Peter S. Hendricks
International Journal of Drug Policy (2019) Vol. 70, pp. 33-39
Closed Access | Times Cited: 60
The therapeutic potential of microdosing psychedelics in depression
Kim P. C. Kuypers
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 60
Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders
Toby Lea, Nicole Amada, Henrik Jungaberle, et al.
Psychopharmacology (2020) Vol. 237, Iss. 5, pp. 1521-1532
Closed Access | Times Cited: 56
Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine
Briana K. Chen, Victor M. Luna, Christina T. LaGamma, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 9, pp. 1545-1556
Open Access | Times Cited: 52
Psychedelic Research and the Need for Transparency: Polishing Alice’s Looking Glass
Rotem Petranker, Thomas Anderson, Norman A. S. Farb
Frontiers in Psychology (2020) Vol. 11
Open Access | Times Cited: 52
Psychedelics as a Treatment for Alzheimer’s Disease Dementia
Simon Vann Jones, Allison O’Kelly
Frontiers in Synaptic Neuroscience (2020) Vol. 12
Open Access | Times Cited: 51
Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings
Carla Pallavicini, Federico Cavanna, Federico Zamberlán, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 406-420
Closed Access | Times Cited: 48
LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility
Isabel Wießner, Rodolfo Olivieri, Marcelo Falchi, et al.
European Neuropsychopharmacology (2022) Vol. 58, pp. 7-19
Closed Access | Times Cited: 32
LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking
Isabel Wießner, Marcelo Falchi, Lucas Oliveira Maia, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 3, pp. 348-359
Open Access | Times Cited: 28
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Michael Tagen, Daniel Mantuani, Liron van Heerden, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 9, pp. 876-890
Closed Access | Times Cited: 20
Psilocybin’s effects on cognition and creativity: A scoping review
Justin N Bonnieux, Baeleigh VanderZwaag, Zahra Premji, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 635-648
Open Access | Times Cited: 17
Keeping the promise: a critique of the current state of microdosing research
Rotem Petranker, Thomas Anderson, Emily C. Fewster, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 6
Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review
Genís Oña, José Carlos Bouso
Neuroscience & Biobehavioral Reviews (2020) Vol. 119, pp. 194-203
Closed Access | Times Cited: 44
Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis
Klára Gotvaldová, Kateřina Hájková, Jan Borovička, et al.
Drug Testing and Analysis (2020) Vol. 13, Iss. 2, pp. 439-446
Closed Access | Times Cited: 43
Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention
Rotem Petranker, Thomas Anderson, Larissa J. Maier, et al.
Journal of Psychopharmacology (2020) Vol. 36, Iss. 1, pp. 85-96
Open Access | Times Cited: 40
Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study
Michiel van Elk, George Fejer, Pascal Lempe, et al.
Psychopharmacology (2021) Vol. 239, Iss. 6, pp. 1705-1720
Open Access | Times Cited: 38
Nootropic effects of LSD: Behavioral, molecular and computational evidence
Isis M. Ornelas, Felipe A. Cini, Isabel Wießner, et al.
Experimental Neurology (2022) Vol. 356, pp. 114148-114148
Open Access | Times Cited: 24
Who are you after psychedelics? A systematic review and a meta-analysis of the magnitude of long-term effects of serotonergic psychedelics on cognition/creativity, emotional processing and personality
Ivana Solaja, Kate Haldane, Natasha L. Mason, et al.
Neuroscience & Biobehavioral Reviews (2024) Vol. 158, pp. 105570-105570
Closed Access | Times Cited: 5
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research
Vince Polito, Paul Liknaitzky
Journal of Psychopharmacology (2024) Vol. 38, Iss. 8, pp. 701-711
Open Access | Times Cited: 5
Psychedelics and potential benefits in “healthy normals”: A review of the literature
Sam Gandy
Journal of Psychedelic Studies (2019) Vol. 3, Iss. 3, pp. 280-287
Open Access | Times Cited: 36
Contextual Parameters Associated with Positive and Negative Mental Health in Recreational Psychedelic Users
Kevin O. St. Arnaud, Donald Sharpe
Journal of Psychoactive Drugs (2022) Vol. 55, Iss. 1, pp. 30-39
Closed Access | Times Cited: 21
N, N-dimethyltryptamine (DMT) in rodent brain: Concentrations, distribution, and recent pharmacological data
Steven A. Barker
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111259-111259
Closed Access

Scroll to top